<div class="headers"><div>Figure 4. Combined score of abdominal pain and loose stool frequency in patients with CD. Percentage change from baseline in APS and LSFS in the overall ITT (A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations after VDZ or PBO administration. ®Data points represent adjusted % change from BL mean, where adjustment is for subscore BL value and treatment. Error bars represent SE. '’Difference adjusted % change [VDZ - PBO] = adjusted mean % change from BL for VDZ -adjusted mean % change from BL for PBO. Upper limit of 95% Cl <0 indicates statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. Patients with baseline APS = 0 and LSFS = 0 were excluded from this analysis. APS, abdominal pain subscore; BL, baseline; Cl, confidence interval; LSFS, loose stool frequency subscore; NS, nonsignificance; PBO, placebo; SE, standard error; VDZ, vedolizumab.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>28(AB)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 4. Combined score of abdominal pain and loose stool frequency in patients with CD. Percentage change from baseline in APS and LSFS in the overall ITT (A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations after VDZ or PBO administration. ®Data points represent adjusted % change from BL mean, where adjustment is for subscore BL value and treatment. Error bars represent SE. '’Difference adjusted % change [VDZ - PBO] = adjusted mean % change from BL for VDZ -adjusted mean % change from BL for PBO. Upper limit of 95% Cl <0 indicates statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. Patients with baseline APS = 0 and LSFS = 0 were excluded from this analysis. APS, abdominal pain subscore; BL, baseline; Cl, confidence interval; LSFS, loose stool frequency subscore; NS, nonsignificance; PBO, placebo; SE, standard error; VDZ, vedolizumab.</p></td>
</tr>
</tbody>
</table>
